Posted On: 08/17/2016 9:06:08 AM
Post# of 273317
Fennec Pharmaceuticals Inc (FENCF) 2.0349 $FENCF
Fennec Provides Corporate Update and Announces Second Quarter 2016 Results
Marketwire Canada - Fri Aug 12, 5:00AM CDT
RESEARCH TRIANGLE PARK, NORTH CAROLINA--(Marketwired - Aug 12, 2016) -
FRX.TO: 2.64 (unch)
Fennec Announces Appointment of Marco Brughera to the Board of Directors
Marketwired - Thu Aug 11, 5:01AM CDT
RESEARCH TRIANGLE PARK, NORTH CAROLINA--(Marketwired - Aug 11, 2016) - Fennec Pharmaceuticals Inc. (TSX:FRX)(OTCQB:FENCF), a specialty pharmaceutical company focused on the development of Sodium Thiosulfate (STS) for the prevention of platinum-induced ototoxicity in pediatric patients, announced today the appointment of Marco Brughera, DVM, CEO and Global Head of Sigma Tau Rare Disease, to its Board of Directors.
FRX.TO: 2.64 (unch)
Fennec Announces Results of Annual Meeting
Marketwire Canada - Wed Jun 08, 4:00PM CDT
RESEARCH TRIANGLE PARK, NORTH CAROLINA--(Marketwired - Jun 8, 2016) - Fennec Pharmaceuticals Inc. (TSX:FRX)(OTCQB:FENCF) today announced that the nominees listed in the management proxy circular dated May 9, 2016 (the "Circular"
for the Annual Meeting of Shareholders were elected as directors of the Company at the Annual Meeting of Shareholders held in Boston, Massachusetts on June 8, 2016 (the "Meeting". Detailed results of the vote for the election of directors are set out below:
FRX.TO: 2.64 (unch)
Fennec Announces Interim Results of SIOPEL 6 Study on Sodium Thiosulfate (STS) Presented at the American Association of Clinical Oncology (ASCO) 2016 Meeting
Marketwired - Mon Jun 06, 5:01AM CDT
- No difference in Event free Survival (EFS) and Overall Survival (OS) at 2 years for cisplatin vs cisplatin + STS with no evidence of tumor protection
FRX.TO: 2.64 (unch)
Fennec Announces Upcoming Events and Presentations
Marketwired - Wed May 18, 4:45PM CDT
RESEARCH TRIANGLE PARK, NORTH CAROLINA--(Marketwired - May 18, 2016) - Fennec Pharmaceuticals Inc. (TSX:FRX)(OTCQB:FENCF) (the "Company" or "Fennec", a specialty pharmaceutical company focused on the development of Sodium Thiosulfate (STS) for the prevention of platinum-induced chemotherapy ototoxicity in pediatric patients, announced today upcoming events and presentations:
FRX.TO: 2.64 (unch)
Essetifin Announces Acquisition of Additional Shares of Fennec Pharmaceuticals and Filing of its Early Warning Report
Marketwired - Tue May 17, 7:31AM CDT
ROME, ITALY--(Marketwired - May 17, 2016) - Essetifin S.p.A. (formerly Sigma Tau Finanziaria S.p.A.) (the "Company" or "Essetifin", an Italian investment holding company with recognized experience in the rare diseases sector, announced today that the Company acquired, through the second closing of a non-brokered private placement (the "Offering", 1,538,751 common shares ("Common Shares" in the capital of Fennec Pharmaceuticals Inc. (the "Issuer", which together with the Common Shares acquired in the first closing of the Offering described below represents an aggregate of 2,631,579 Common Shares (the "Purchased Shares", or 19.30% of the Issuer's issued and outstanding Common Shares. The Purchased Shares were acquired at a price per share of US$1.90 for total consideration to the Issuer of US$5,000,000, or CAD$6,497,500, based on the daily noon currency exchange rate on April 8, 2016.
FRX.TO: 2.64 (unch)
Fennec Announces Second Closing of Private Placement
Marketwire Canada - Mon May 16, 10:50AM CDT
RESEARCH TRIANGLE PARK, NORTH CAROLINA--(Marketwired - May 16, 2016) - Fennec Pharmaceuticals Inc. (TSX:FRX)(OTCQB:FENCF) (the "Company" or "Fennec", a specialty pharmaceutical company focused on the development of Sodium Thiosulfate (STS) for the prevention of platinum-induced chemotherapy ototoxicity in pediatric patients, announced today that it has completed the second closing of the previously announced non-brokered US$5,000,000 private placement (the "Offering". On the second closing, Essetifin SpA (formerly Sigma Tau Finanziaria SpA) acquired 1,538,751 common shares for gross proceeds of US$2,923,626.90. Together with the 1,092,828 common shares issued to it on the first closing, Essetifin SpA now holds 2,631,579 common shares, which represents 19.30% of the Company's issued and outstanding shares, and has become an insider of the Company, as that term is defined in applicable Canadian securities laws. Total gross proceeds of the Offering were US$5,000,000 and all shares were issued at a price of US$1.90 per Share. The current number of outstanding Shares, after giving effect to the Offering, is 13,638,567.
FRX.TO: 2.64 (unch)
Fennec Provides Corporate Update and Announces First Quarter 2016 Results
Marketwire Canada - Thu May 12, 5:01AM CDT
- SIOPEL 6 Interim Results Oral Presentation at ASCO 2016 on June 5
FRX.TO: 2.64 (unch)
Fennec Announces Sodium Thiosulfate Presentation for Prevention of Ototoxicity in Children at ASCO Meeting
Marketwired - Wed Apr 20, 9:14PM CDT
Fennec Pharmaceuticals Inc. (TSX: FRX)(OTCQB: FENCF) (the "Company" or "Fennec", a specialty pharmaceutical company focused on the development of Sodium Thiosulfate (STS) for the prevention of platinum-induced chemotherapy ototoxicity in pediatric patients, announced today that interim results from "SIOPEL 6: A multi-centre open label randomised phase III trial of the efficacy of sodium thiosulfate (STS) in reducing ototoxicity in patients receiving cisplatin (Cis) monotherapy for standard risk hepatoblastoma (SR-HB)" has been accepted for an oral presentation at the 2016 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, Illinois.
FRX.TO: 2.64 (unch)
Fennec Announces $5.0 Million Private Placement of Common Shares by Sigma Tau Finanziaria
Marketwired - Fri Apr 08, 7:00AM CDT
Fennec Pharmaceuticals Inc. (TSX: FRX)(OTCQB: FENCF) (the "Company" or "Fennec", a specialty pharmaceutical company focused on the development of Sodium Thiosulfate (STS) for the prevention of platinum-induced chemotherapy ototoxicity in pediatric patients, announced today that it intends to complete a non-brokered private placement (the "Offering" of 2,631,579 common shares for gross proceeds of US$5,000,000. The common shares of the Company (the "Shares" will be issued at a price of US$1.90 per Share. The current number of outstanding Shares, without giving effect to the Offering, is 11,006,988.
FRX.TO: 2.64 (unch)
Fennec Provides Corporate Update and Announces Fiscal Year Ended December 31, 2015 Financial Results
Marketwired - Mon Mar 28, 3:11PM CDT
Fennec Pharmaceuticals Inc. (TSX: FRX)(OTCQB: FENCF), a specialty pharmaceutical company focused on the development of Sodium Thiosulfate (STS) for the prevention of platinum-induced ototoxicity in pediatric patients, today reported its corporate update and financial results for the year ended December 31, 2015.
FRX.TO: 2.64 (unch)
Fennec Provides Corporate Update and Announces Second Quarter 2016 Results
Marketwire Canada - Fri Aug 12, 5:00AM CDT
RESEARCH TRIANGLE PARK, NORTH CAROLINA--(Marketwired - Aug 12, 2016) -
FRX.TO: 2.64 (unch)
Fennec Announces Appointment of Marco Brughera to the Board of Directors
Marketwired - Thu Aug 11, 5:01AM CDT
RESEARCH TRIANGLE PARK, NORTH CAROLINA--(Marketwired - Aug 11, 2016) - Fennec Pharmaceuticals Inc. (TSX:FRX)(OTCQB:FENCF), a specialty pharmaceutical company focused on the development of Sodium Thiosulfate (STS) for the prevention of platinum-induced ototoxicity in pediatric patients, announced today the appointment of Marco Brughera, DVM, CEO and Global Head of Sigma Tau Rare Disease, to its Board of Directors.
FRX.TO: 2.64 (unch)
Fennec Announces Results of Annual Meeting
Marketwire Canada - Wed Jun 08, 4:00PM CDT
RESEARCH TRIANGLE PARK, NORTH CAROLINA--(Marketwired - Jun 8, 2016) - Fennec Pharmaceuticals Inc. (TSX:FRX)(OTCQB:FENCF) today announced that the nominees listed in the management proxy circular dated May 9, 2016 (the "Circular"
for the Annual Meeting of Shareholders were elected as directors of the Company at the Annual Meeting of Shareholders held in Boston, Massachusetts on June 8, 2016 (the "Meeting". Detailed results of the vote for the election of directors are set out below: FRX.TO: 2.64 (unch)
Fennec Announces Interim Results of SIOPEL 6 Study on Sodium Thiosulfate (STS) Presented at the American Association of Clinical Oncology (ASCO) 2016 Meeting
Marketwired - Mon Jun 06, 5:01AM CDT
- No difference in Event free Survival (EFS) and Overall Survival (OS) at 2 years for cisplatin vs cisplatin + STS with no evidence of tumor protection
FRX.TO: 2.64 (unch)
Fennec Announces Upcoming Events and Presentations
Marketwired - Wed May 18, 4:45PM CDT
RESEARCH TRIANGLE PARK, NORTH CAROLINA--(Marketwired - May 18, 2016) - Fennec Pharmaceuticals Inc. (TSX:FRX)(OTCQB:FENCF) (the "Company" or "Fennec"
, a specialty pharmaceutical company focused on the development of Sodium Thiosulfate (STS) for the prevention of platinum-induced chemotherapy ototoxicity in pediatric patients, announced today upcoming events and presentations: FRX.TO: 2.64 (unch)
Essetifin Announces Acquisition of Additional Shares of Fennec Pharmaceuticals and Filing of its Early Warning Report
Marketwired - Tue May 17, 7:31AM CDT
ROME, ITALY--(Marketwired - May 17, 2016) - Essetifin S.p.A. (formerly Sigma Tau Finanziaria S.p.A.) (the "Company" or "Essetifin"
, an Italian investment holding company with recognized experience in the rare diseases sector, announced today that the Company acquired, through the second closing of a non-brokered private placement (the "Offering", 1,538,751 common shares ("Common Shares" in the capital of Fennec Pharmaceuticals Inc. (the "Issuer", which together with the Common Shares acquired in the first closing of the Offering described below represents an aggregate of 2,631,579 Common Shares (the "Purchased Shares", or 19.30% of the Issuer's issued and outstanding Common Shares. The Purchased Shares were acquired at a price per share of US$1.90 for total consideration to the Issuer of US$5,000,000, or CAD$6,497,500, based on the daily noon currency exchange rate on April 8, 2016. FRX.TO: 2.64 (unch)
Fennec Announces Second Closing of Private Placement
Marketwire Canada - Mon May 16, 10:50AM CDT
RESEARCH TRIANGLE PARK, NORTH CAROLINA--(Marketwired - May 16, 2016) - Fennec Pharmaceuticals Inc. (TSX:FRX)(OTCQB:FENCF) (the "Company" or "Fennec"
, a specialty pharmaceutical company focused on the development of Sodium Thiosulfate (STS) for the prevention of platinum-induced chemotherapy ototoxicity in pediatric patients, announced today that it has completed the second closing of the previously announced non-brokered US$5,000,000 private placement (the "Offering". On the second closing, Essetifin SpA (formerly Sigma Tau Finanziaria SpA) acquired 1,538,751 common shares for gross proceeds of US$2,923,626.90. Together with the 1,092,828 common shares issued to it on the first closing, Essetifin SpA now holds 2,631,579 common shares, which represents 19.30% of the Company's issued and outstanding shares, and has become an insider of the Company, as that term is defined in applicable Canadian securities laws. Total gross proceeds of the Offering were US$5,000,000 and all shares were issued at a price of US$1.90 per Share. The current number of outstanding Shares, after giving effect to the Offering, is 13,638,567. FRX.TO: 2.64 (unch)
Fennec Provides Corporate Update and Announces First Quarter 2016 Results
Marketwire Canada - Thu May 12, 5:01AM CDT
- SIOPEL 6 Interim Results Oral Presentation at ASCO 2016 on June 5
FRX.TO: 2.64 (unch)
Fennec Announces Sodium Thiosulfate Presentation for Prevention of Ototoxicity in Children at ASCO Meeting
Marketwired - Wed Apr 20, 9:14PM CDT
Fennec Pharmaceuticals Inc. (TSX: FRX)(OTCQB: FENCF) (the "Company" or "Fennec"
, a specialty pharmaceutical company focused on the development of Sodium Thiosulfate (STS) for the prevention of platinum-induced chemotherapy ototoxicity in pediatric patients, announced today that interim results from "SIOPEL 6: A multi-centre open label randomised phase III trial of the efficacy of sodium thiosulfate (STS) in reducing ototoxicity in patients receiving cisplatin (Cis) monotherapy for standard risk hepatoblastoma (SR-HB)" has been accepted for an oral presentation at the 2016 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, Illinois. FRX.TO: 2.64 (unch)
Fennec Announces $5.0 Million Private Placement of Common Shares by Sigma Tau Finanziaria
Marketwired - Fri Apr 08, 7:00AM CDT
Fennec Pharmaceuticals Inc. (TSX: FRX)(OTCQB: FENCF) (the "Company" or "Fennec"
, a specialty pharmaceutical company focused on the development of Sodium Thiosulfate (STS) for the prevention of platinum-induced chemotherapy ototoxicity in pediatric patients, announced today that it intends to complete a non-brokered private placement (the "Offering" of 2,631,579 common shares for gross proceeds of US$5,000,000. The common shares of the Company (the "Shares" will be issued at a price of US$1.90 per Share. The current number of outstanding Shares, without giving effect to the Offering, is 11,006,988. FRX.TO: 2.64 (unch)
Fennec Provides Corporate Update and Announces Fiscal Year Ended December 31, 2015 Financial Results
Marketwired - Mon Mar 28, 3:11PM CDT
Fennec Pharmaceuticals Inc. (TSX: FRX)(OTCQB: FENCF), a specialty pharmaceutical company focused on the development of Sodium Thiosulfate (STS) for the prevention of platinum-induced ototoxicity in pediatric patients, today reported its corporate update and financial results for the year ended December 31, 2015.
FRX.TO: 2.64 (unch)
(0)
(0)
